Overview
Journey Clinical provides Ketamine-Assisted Psychotherapy (KAP) for depression, anxiety, and PTSD. It acts as an in-house treatment partner, guiding patients from initial consultation to prescription, administration, and psychotherapy within a coordinated care plan. The treatment combines ketamine’s pharmacological effects with structured psychotherapy to address symptoms from multiple angles, with ongoing support and follow-up. Its differentiator is a patient-centered, collaborative care model led by a team of MDs, PhDs, and licensed clinicians who tailor plans to each patient’s needs, aiming to improve mental health outcomes through accessible, personalized therapy.
Work here?Claim your company
Simplify's take
What believers are saying
- DEA telemedicine flexibilities stay open through December 31, 2026, supporting remote ketamine prescribing.
- Journey Clinical says major insurers cover KAP, and patients receive reimbursement in 30 states.
- The 2026 White House executive order boosts psychedelic medicine attention and future access pathways.
What critics are saying
- DEA telemedicine relief expires December 31, 2026; tighter rules would break its remote workflow.
- Georgia's 2026 ketamine-clinic law signals state licensing, ownership, and staffing scrutiny spreading nationwide.
- FDA ketamine safety warnings and compounding crackdowns threaten prescriber confidence, referrals, and Journey Clinical's existential market.
What makes Journey Clinical unique
- Journey Clinical runs therapist-led KAP with in-network prescribers across 30 states.
- It claims the largest U.S. psychedelic-assisted psychotherapy provider network, anchored by thousands of therapists.
- Its model keeps therapists independent while Journey Clinical handles medical oversight and prescribing.
Help us improve and share your feedback! Did you find this helpful?